Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: A controlled experimental animal study

Reproductive Biology and Endocrinology

Volumn 11, Issue 1, 2013, Pages

  Li, Xiaoyan ^a   Kang, Xiang ^a   Deng, Qingchun ^a   Cai, Jing ^a   Wang, Zehua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemotherapy; GnRH agonist; GnRH antagonist; Ovarian protection

Indexed keywords

CETRORELIX; CISPLATIN; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; TRIPTORELIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ESTRUS CYCLE; EXPERIMENTAL STUDY; FEMALE; HISTOLOGY; NONHUMAN; OVARY FOLLICLE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COUNT; CISPLATIN; ESTRADIOL; ESTROUS CYCLE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LUTEINIZING HORMONE; MODELS, ANIMAL; OVARIAN FOLLICLE; OVARY; RATS; RATS, WISTAR; TIME FACTORS; TRIPTORELIN PAMOATE;

ANIMALIA; RATTUS;

EID: 84874397173     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-11-16     Document Type: Article

References (31)

1. Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002, 38:1701-1707. 10.1016/S0959-8049(02)00161-2, 12175685.
2. Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv 2007, 62:58-72. 10.1097/01.ogx.0000251029.93792.5d, 17176489.
3. Meraner V, Gamper EM, Grahmann A, Giesinger JM, Wiesbauer P, Sztankay M, Zeimet AG, Sperner-Unterweger B, Holzner B. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer 2012, 12:77. 10.1186/1471-2407-12-77, 3308918, 22373218.
4. Kim SS. Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril 2006, 85:1-11. 10.1016/j.fertnstert.2005.04.071, 16412718.
5. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008, 14:543-552. 10.1093/humupd/dmn022, 18824495.
6. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000, 9:401-405. 10.1191/096120300678828596, 10981642.
7. Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol 2012, 26:379-390. 10.1016/j.bpobgyn.2011.11.008, 22281514.
8. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005, 34:40-43.
9. Huang YH, Zhao XJ, Zhang QH, Xin XY. The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis. Gynecol Oncol 2009, 112:409-414. 10.1016/j.ygyno.2008.09.044, 19038435.
10. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007, 12:1044-1054. 10.1634/theoncologist.12-9-1044, 17914074.
11. Parborell F, Irusta G, Vitale A, Gonzalez O, Pecci A, Tesone M. Gonadotropin-releasing hormone antagonist antide inhibits apoptosis of preovulatory follicle cells in rat ovary. Biol Reprod 2005, 72:659-666. 10.1095/biolreprod.104.034454, 15564600.
12. von Wolff M, Kammerer U, Kollmann Z, Santi A, Dietl J, Frambach T. Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up. Fertil Steril 2011, 95:452-454. 10.1016/j.fertnstert.2010.08.053, 20869706.
13. Roth CL, Brendel L, Ruckert C, Hartmann K. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine. Horm Res 2005, 63:257-262. 10.1159/000086685, 15995342.
14. Mueller A, Maltaris T, Haberle L, Hoffmann I, Beckmann MW, Dittrich R. Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot study. Fertil Steril 2009, 91:647-648. 10.1016/j.fertnstert.2007.11.066, 18423456.
15. Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004, 25:90-92.
16. Marcondes FK, Bianchi FJ, Tanno AP. Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol 2002, 62:609-614. 10.1590/S1519-69842002000400008, 12659010.
17. Sagsoz N, Kisa U, Apan A. Ischaemia-reperfusion injury of rat ovary and the effects of vitamin C, mannitol and verapamil. Hum Reprod 2002, 17:2972-2976. 10.1093/humrep/17.11.2972, 12407059.
18. Kreuser ED, Hetzel WD, Billia DO, Thiel E. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev 1990, 17:169-175. 10.1016/0305-7372(90)90043-F, 2176931.
19. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996, 11:1620-1626. 10.1093/oxfordjournals.humrep.a019457, 8921104.
20. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009, 91:694-697. 10.1016/j.fertnstert.2007.12.044, 18675959.
21. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009, 117:561-567. 10.1007/s10549-009-0313-5, 19153828.
22. Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S, Ozturk A. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril 2010, 93:1609-1614. 10.1016/j.fertnstert.2009.02.054, 19339002.
23. Tan SJ, Yeh YC, Shang WJ, Wu GJ, Liu JY, Chen CH. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model. Eur J Obstet Gynecol Reprod Biol 2010, 149:182-185. 10.1016/j.ejogrb.2009.12.028, 20074846.
24. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011, 306:269-276. 10.1001/jama.2011.991, 21771987.
25. Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, Ott HW, Hofer S, Pluetschow A, Diehl V. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010, 21:2052-2060. 10.1093/annonc/mdq066, 20305034.
26. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004, 19:1294-1299. 10.1093/humrep/deh257, 15117898.
27. Lemos CN, Reis FM, Pena GN, Silveira LC, Camargos AF. Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide. Reprod Biol Endocrinol 2010, 8:51. 10.1186/1477-7827-8-51, 2885402, 20482803.
28. Zhao XJ, Huang YH, Yu YC, Xin XY. GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats. Gynecol Oncol 2010, 118:69-75. 10.1016/j.ygyno.2010.03.021, 20417958.
29. Whitehead J, Toledo MG, Stern CJ. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy. Aust N Z J Obstet Gynaecol 2011, 51:452-454. 10.1111/j.1479-828X.2011.01346.x, 21810087.
30. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 2005, 83:1333-1338. 10.1016/j.fertnstert.2004.12.030, 15866565.
31. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004, 428:145-150. 10.1038/nature02316, 15014492.